Table 2.
Prediction temporality and sample size with respective events in included models
| Articles | Country | Setting | Data source | Study design | Baseline time(t0) | Number of participants included | Number of events and percent | GI test time (t1) | Primary outcome |
|---|---|---|---|---|---|---|---|---|---|
| Bengtson 2022 | USA | Clinical (hospital-based) | Questionnaires | Prospective cohort | 2 days PP | 203 | 71 (35%) | 4–12 weeks | IGT |
| Man 2021 | USA | Both | Secondary data | RCT | History | 317 | 82 (25.9%) | 3 years | DM |
| Bartáková 2021 | Czech Republic | Clinical (hospital-based) | EHRs and questionnaires | Retrospective cohort (cross-sectional) | GDM Dx | 244 | 22 (9%) | 6–12 weeks | GI |
| Joglekar 2020 | Australia | Clinical (hospital-based) | Questionnaires | Prospective cohort | 12 Weeks pp | 103 | 21 (20.4%) | (10 years) | T2DM |
| Muche, 2020 | Ethiopia | Clinical (hospital-based) | MR and questionnaires | Prospective cohort study | GDM Dx | 112 | 24 (21.4%) | 6–12 weeks | GI |
| Khan 2019 | Germany | Clinical (hospital-based) | EHRs | Nested case control study | 6–9 Weeks pp | 140 | 55(39.3%) | 2 years | DM |
| Kondo 2018 | Japan | Clinical (hospital-based) | MR | Retrospective cohort study | GDM Dx | 123 | 45 (36.6%) | 8–12 weeks | GI |
| Allalou 2016 | USA | Clinical (hospital-based) | MR and questionnaires | Prospective cohort | 6–9 Weeks pp | 1010 | 122 (12.08%) | 4 years | T2DM |
| Ignell 2016 | Sweden | Clinical (hospital-based) | EHRs | A prospective cohort study | GDM Dx | 362 | 72 (19%) | 5 years | DM |
| Köhler 2016 | Germany | Clinical (hospital-based) | Questionnaires | A prospective cohort study | GDM Dx | 257 | 110 (42.8%) | 20 years | DM |
| Bartáková 2015 | Czech Republic | Clinical (hospital-based) | EHRs | Retrospective cohort | GDM Dx | 305 | 51 (16.7%) | 1 year | GA |
| Lappas 2015 | Australia | Clinical (hospital-based) | MR and questionnaires | Prospective cohort | 12 Month pp | 104 | 21 (20.2%) | 8–10 years | T2DM |
| Cormier 2015 | Canada | Community based | Survey | A cohort study | PP | 214 | 135 (63.08%) | 3 years | pDM & DM |
| Kwak 2012 | South Korea | Clinical (hospital-based) | MR | Prospective cohort study | GDM Dx | 395 | 116 (29.4%) | 45 months | T2DM |
| Kjos SL 1995 | USA | Clinical (hospital-based) | MR and questionnaires | Prospective cohort | 4–16 Weeks | 671 | 146 (21.7%) | 5–7 years | NIDDM |
EHRs electronic health records, MR medical records, GDM Dx gestational diabetes mellitus diagnosis, PP postpartum, T2DM type 2 diabetes mellitus, GI glucose intolerance, NIDDM non-insulin dependent diabetes mellitus, GA glucose abnormality, pDM primary diabetes mellitus, DM diabetes mellitus, IGT impaired glucose intolerance, USA United States of America, RCT randomized controlled trial